Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 16/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690797 | 0.77 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL14892841 | 0.77 | ALDH1A1 (0.67) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL24435218 | 0.76 | ALDH1A1 (0.73) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL30556699 | 0.76 | HSD17B10 (0.44) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL23107927 | 0.75 | ALDH1A1 (0.80) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL25696791 | 0.74 | HSD17B10 (0.53) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL26684632 | 0.74 | HSD17B10 (0.53) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL20064103 | 0.73 | ALDH1A1 (0.52) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL26141085 | 0.73 | HSD17B10 (0.41) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 | |
| SCHEMBL30059839 | 0.72 | HSD17B10 (0.54) | HSD17B10ALDH1A1HPGDCYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | HSD17B10 321/4885ALDH1A1 1088/4885HPGD 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.